Kyoung Sik Park - Search Results

Year	Number of Results
2002	1
2004	1
2006	1
2007	3
2009	1
2010	5
2011	3
2012	6
2013	4
2014	8
2015	12
2016	3
2017	4
2019	4
2020	3
2021	6
2022	9
2023	6
2024	1

1

Pharmacological Effects of Centella asiatica on Skin Diseases: Evidence and Possible Mechanisms.

Park KS. Park KS. Evid Based Complement Alternat Med. 2021 Nov 20;2021:5462633. doi: 10.1155/2021/5462633. eCollection 2021. Evid Based Complement Alternat Med. 2021. PMID: 34845411 Free PMC article. Review.

2

An idiopathic gigantomastia.

Cho MJ, Yang JH, Choi HG, Kim WS, Yu YB, Park KS. Cho MJ, et al. Among authors: park ks. Ann Surg Treat Res. 2015 Mar;88(3):166-9. doi: 10.4174/astr.2015.88.3.166. Epub 2015 Feb 27. Ann Surg Treat Res. 2015. PMID: 25741497 Free PMC article.

3

PET/MRI and Novel Targets for Breast Cancer.

Chung HW, Park KS, Lim I, Noh WC, Yoo YB, Nam SE, So Y, Lee EJ. Chung HW, et al. Among authors: park ks. Biomedicines. 2024 Jan 12;12(1):172. doi: 10.3390/biomedicines12010172. Biomedicines. 2024. PMID: 38255277 Free PMC article. Review.

4

Current Status of Genetically Engineered Pig to Monkey Kidney Xenotransplantation in Korea.

Hwang SA, Park KS, Kim WS, Shin KC, Ahn YR, Kim JS, Chee HK, Yang HS, Oh KB, Choi KM, Hwang JH, Hur CG, Yun IJ. Hwang SA, et al. Among authors: park ks. Transplant Proc. 2023 May;55(4):1043-1047. doi: 10.1016/j.transproceed.2023.03.060. Epub 2023 May 12. Transplant Proc. 2023. PMID: 37179178

5

Epigenetic Factors as Etiological Agents, Diagnostic Markers, and Therapeutic Targets for Luminal Breast Cancer.

Thang NX, Yoo S, La H, Lee H, Park C, Park KS, Hong K. Thang NX, et al. Among authors: park ks. Biomedicines. 2022 Mar 23;10(4):748. doi: 10.3390/biomedicines10040748. Biomedicines. 2022. PMID: 35453496 Free PMC article. Review.

6

Anti-oncogenic effects of dutasteride, a dual 5-alpha reductase inhibitor and a drug for benign prostate hyperplasia, in bladder cancer.

Seok J, Kwak HJ, Kwak Y, Lee M, Park KS, Kim A, Cho SG. Seok J, et al. Among authors: park ks. J Transl Med. 2023 Feb 18;21(1):129. doi: 10.1186/s12967-023-03972-4. J Transl Med. 2023. PMID: 36800968 Free PMC article.

7

Fatty acid synthetase expression in triple-negative breast cancer.

Park JH, Han HS, Lim SD, Kim WY, Park KS, Yoo YB, Lee SE, Kim WS. Park JH, et al. Among authors: park ks. J Pathol Transl Med. 2022 Mar;56(2):73-80. doi: 10.4132/jptm.2021.10.27. Epub 2022 Jan 21. J Pathol Transl Med. 2022. PMID: 35051326 Free PMC article.

8

TTYH3 Modulates Bladder Cancer Proliferation and Metastasis via FGFR1/H-Ras/A-Raf/MEK/ERK Pathway.

Biswas PK, Kwak Y, Kim A, Seok J, Kwak HJ, Lee M, Dayem AA, Song K, Park JY, Park KS, Shin HJ, Cho SG. Biswas PK, et al. Among authors: park ks. Int J Mol Sci. 2022 Sep 10;23(18):10496. doi: 10.3390/ijms231810496. Int J Mol Sci. 2022. PMID: 36142409 Free PMC article.

9

Overexpression of FRAT1 protein is closely related to triple-negative breast cancer.

Nam SE, Ko YS, Park KS, Jin T, Yoo YB, Yang JH, Kim WY, Han HS, Lim SD, Lee SE, Kim WS. Nam SE, et al. Among authors: park ks. Ann Surg Treat Res. 2022 Aug;103(2):63-71. doi: 10.4174/astr.2022.103.2.63. Epub 2022 Aug 5. Ann Surg Treat Res. 2022. PMID: 36017142 Free PMC article.

10

BRCA1/2 Serves as a Biomarker for Poor Prognosis in Breast Carcinoma.

Jin TY, Park KS, Nam SE, Yoo YB, Park WS, Yun IJ. Jin TY, et al. Among authors: park ks. Int J Mol Sci. 2022 Mar 29;23(7):3754. doi: 10.3390/ijms23073754. Int J Mol Sci. 2022. PMID: 35409110 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

74 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

74 results

Results by year